Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

ProKidney Presents Rilparencel Mechanism-of-Action Findings in Advanced Kidney Disease

By Public Technologies
  • ProKidney expects Phase 3 PROACT 1 enrollment to exceed 500 patients, up from 470, with completion targeted for Q1 2027.
  • Topline rilparencel eGFR slope results are expected in Q2 2027; the efficacy analysis is expected to include approximately 320 patients.
  • A biologics license application submission is targeted for Q1 2028, with accelerated approval and commercial launch anticipated in the first half of 2029.
  • Confirmatory endpoint results supporting full approval are expected in the second half of 2029.
  • Translational studies suggest rilparencel reduces oxidative damage and inflammatory signaling while supporting vascular integrity under chronic kidney disease-relevant conditions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prokidney Corp. published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.